Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
downgraded at Baird from Outperform to Neutral. $31 price target. Latest Ampyra survey indicates lower projected patient share.
rated new Hold at Jefferies. It will still take several more months to quantify the final Macondo costs.
downgraded at Goldman to Neutral. Company could be hurt by lower near-term hospital CapEx spending.
rated new Buy at Jefferies. $75 price target. Asset sales should benefit the company.
upgraded at Goldman to Buy, Goldman Sachs said. $53 price target. Stock has lagged its peers, but is already pricing in lower surgical volumes.
rated new Buy at Keybanc. $74 price target. Company has exposure to robust end-market demand.
rated new Hold at Keybanc. Company lacks near-term catalysts.
upgraded at Keybanc from Hold to Buy. $69 price target. Company should benefit from a recovery in demand for autos and commercial vehicles.
This article was written by a staff member of TheStreet.